DDInter1002 DDInter1676
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Ixazomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vibrio cholerae CVD 103-HgR strain live antigen
Ixazomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Filgrastim
Ixazomib {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Ixazomib {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Ixazomib may lead to a major life threatening interaction when taken with Clozapine
Ixazomib may lead to a major life threatening interaction when taken with Rotavirus vaccine